参考文献/References:
[1] 霍豆, 秦爽, 吴永昌, 等. 血清总轻链与游离轻链定量检测在多发性骨髓瘤诊断中的临床价值探讨[J].现代检验医学杂志,2020,35(4):87-88,157.HUO Dou, QIN Shuang, WU Yongchang, et al. Clinicalvalue of quantitative detection of sTLC and sFLC indiagnosis of multiple myeloma [J]. Journal of ModernLaboratory Medicine, 2020,35(4): 87-88,157.
[2] ORMOND F A, CARNEIRO B C, PASTORE D, et al.Whole-Body imaging of multiple myeloma: diagnosticcriteria[J]. Radiographics, 2019, 39(4): 1077-1097.
[3] 田鸿来．莪术醇对人多发性骨髓瘤细胞增殖抑制及促凋亡作用的研究[D]. 济南: 山东大学,2018.TIAN Honglai.The study of curcumol on proliferationand apoptosis of multiple myeloma cells[D].Jinan:Shandong University,2018.
[4] 李玉玮．多发性骨髓瘤伴肾损害患者的临床特点及危险因素分析[D]．苏州：苏州大学，2019．LI Yuwei.Clinical features and risk factorsof multiple myeloma patients with renalimpairment[D]. Suzhou:Soochow University, 2019.
[5] NAKAYA A, FUJITA S, SATAKE A, et al. Impactof CRAB symptoms in survival of patients withsymptomatic myeloma in novel agent era[J].Hematology Reports, 2017, 9(1): 6887.
[6] DOTTERWEICH J, TOWER R J, BRANDL A, et al.The KISS1 receptor as an in vivo microenvironmentimaging biomarker of multiple myeloma bonedisease[J]. PLoS One, 2016, 11(5): e0155087.
[7] XU Song, DE VEIRMAN K, DE BECKER A, etal. Mesenchymal stem cells in multiple myeloma: atherapeutical tool or target[J]. Leukemia, 2018, 32(7):1500-1514.
[8] ZHANG Guihua, MIAO Fa’an, XU Jinge, et al.Mesenchymal stem cells from bone marrow regulateinvasion and drug resistance of multiple myeloma cellsby secreting chemokine CXCL13[J]. Bosnian Journalof Basic Medical Sciences, 2020, 20(2) : 209-217.
[9] URBANIAK-KUJDA D, KAPELKO-SLOWIKK, PRAJS I, et al. Increased expression ofmetalloproteinase-2 and -9 (MMP-2, MMP-9), tissueinhibitor of metalloproteinase-1 and -2 (TIMP-1, TIMP-2), and EMMPRIN (CD147) in multiple myeloma[J].Hematology (Amsterdam, Netherlands), 2016, 21(1):26-33.
[10] SLANY A, HAUDEK-PRINZ V, MESHCHERYAKOVA A,et al. Extracellular matrix remodeling by bone marrowfibroblast-like cells correlates with disease progressionin multiple myeloma[J]. Journal of Proteome Research,2014, 13(2): 844-854.
[11] GUPTA N, KHAN R, KUMAR R, et al. Versican andits associated molecules: potential diagnostic markersfor multiple myeloma[J]. Clinica Chimica Acta, 2015,442(1): 119-124.
[12] PALTA A, KAUR M, TAHLAN A, et al. Evaluationof angiogenesis in multiple myeloma by VEGFimmunoexpression and microvessel density[J]. Journalof Laboratory Physicians, 2020, 12(1): 38-43.
[13] RIBATTI D, VACCA A. New insights in antiangiogenesisin multiple myeloma[J]. InternationalJournal of Molecular Sciences, 2018, 19(7): 2031.
[14] HARMER D, FALANK C, REAGAN M R. Interleukin-6 interweaves the bone marrow microenvironment,bone loss, and multiple myeloma[J]. Frontiers in Endocrinology,2018, 9(1): 788.
[15] TERPOS E, MATSARIDIS D, KOUTOULIDIS V, etal. Dynamic contrast-enhanced magnetic resonanceimaging parameters correlate with advanced revised-ISS and angiopoietin-1/angiopoietin-2 ratio in patientswith multiple myeloma[J]. Annals of Hematology,2017, 96(10): 1707-1714.
[16] JOSH I S , KHAN R , SHARMA M , e t a l .Angiopoietin-2: a potential novel diagnostic markerin multiple myeloma[J]. Clinical Biochemistry, 2011,44(8/9): 590-595.
[17] JONES C I, ZABOLOTSKAYA M V, KING A J, et al.Identification of circulating microRNAs as diagnosticbiomarkers for use in multiple myeloma[J]. BritishJournal of Cancer, 2012, 107(12): 1987-1996.
[18] KUBICZKOVA L, KRYUKOV F, SLABY O, et al.Circulating serum microRNAs as novel diagnosticand prognostic biomarkers for multiple myelomaand monoclonal gammopathy of undeterminedsignificance[J]. Haematologica, 2014, 99(3): 511-518.
[19] ZHU Bingying, JU Shaoqing, CHU Haidan, et al. Thepotential function of microRNAs as biomarkers andtherapeutic targets in multiple myeloma.[J]. OncologyLetters, 2018, 15(5) : 6094-6106.
[20] RONCHETTI D, AGNELLI L, TAIANA E, etal. Distinct lncRNA transcriptional fingerprintscharacterize progressive stages of multiple myeloma[J].Oncotarget, 2016, 7(12): 14814-14830.
[21] YANG Xiangchou, YE Haihao, HE Muqing, et al.LncRNA PDIA3P interacts with c-Myc to regulatecell proliferation via induction of pentose phosphatepathway in multiple myeloma[J]. Biochemical andBiophysical Research Communications, 2018, 498(1) :207-213.
[22] PAN Yafang, CHEN Hongmei, SHEN Xianjuan, etal. Serum level of long noncoding RNA H19 as adiagnostic biomarker of multiple myeloma.[J]. ClinicaChimica Acta, 2018, 480 : 199-205.
[23] ZHUANG Wenzhuo, GE Xueping, YANG Sijun, et al.Upregulation of lncRNA MEG3 promotes osteogenicdifferentiation of mesenchymal stem cells from multiplemyeloma patients by targeting BMP4 transcription[J].Stem Cells, 2015, 33(6): 1985-1997.
[24] GAO Meng, LI Chengyuan, XIAO Han, et al. hsa_circ_0007841: A novel potential biomarker and drugresistance for multiple myeloma.[J]. Frontiers inOncology, 2019, 9 : 1261.
[25] LIU Xiao, TANG Hao, LIU Jing, et al.hsa_circRNA_101237: A novel diagnostic and prognosticbiomarker and potential therapeutic target for multiplemyeloma[J]. Cancer Management and Research, 2020,12(1): 2109-2118.
[26] FENG Yashu, ZHANG Ling, WU Jieying, et al.CircRNA circ_0000190 inhibits the progression ofmultiple myeloma through modulating miR-767-5p/MAPK4 pathway[J]. Journal of Experimental &Clinical Cancer Research : CR, 2019, 38(1): 54.
[27] CASTRO-GINER F, ACETO N. Tracking cancerprogression: from circulating tumor cells tometastasis[J]. Genome Medicine, 2020, 12(1): 31.
[28] GONSALVES W I, RAJKUMAR S V, GUPTA V, etal. Quantification of clonal circulating plasma cellsin newly diagnosed multiple myeloma: implicationsfor redefining high-risk myeloma[J]. Leukemia, 2014,28(10): 2060-2065.
[29] GONSALVES W I, MORICE W G, RAJKUMAR V,et al. Quantification of clonal circulating plasma cellsin relapsed multiple myeloma[J]. British Journal ofHaematology, 2014, 167(4): 500-505.
[30] BIANCHI G, KYLE R A, LARSON D R, et al. Highlevels of peripheral blood circulating plasma cells asa specific risk factor for progression of smolderingmultiple myeloma[J]. Leukemia, 2013, 27(3): 680-685.
[31] GARC?S J J, BRETONES G, BURGOS L, et al.Circulating tumor cells for comprehensive andmultiregional non-invasive genetic characterization ofmultiple myeloma[J]. Leukemia, 2020, 34(11): 3007-3018.
[32] PESSOA L S, HERINGER M, FERRER V P. ctDNAas a cancer biomarker: a broad overview[J]. CriticalReviews in Oncology Hematology, 2020, 155(1):103109.
[33] BUSTOROS M, MOUHIEDDINE T H, DETAPPEA, et al. Established and novel prognostic biomarkersin multiple myeloma[J]. American Society of ClinicalOncology Educational Book / ASCO. American Societyof Clinical Oncology Meeting, 2017, 37(1): 548-560.
[34] MITHRAPRABHU S, MORLEY R, KHONG T, et al.Monitoring tumour burden and therapeutic responsethrough analysis of circulating tumour DNA andextracellular RNA in multiple myeloma patients[J].Leukemia, 2019, 33(8): 2022-2033.
相似文献/References:
[1]韩秀蕊,杨娣娣,李艳春,等.多发性骨髓瘤患者骨髓涂片与骨髓活检同步检查的比较分析[J].现代检验医学杂志,2015,30(03):129.[doi:10.3969/j.issn.1671-7414.2015.03.039]
HAN Xiu-rui,YANG Di-di,LI Yan-chun,et al.Comparative Analysis of Bone Marrow Smears and Biopsies
Synchronous Check for Myeloma Patients[J].Journal of Modern Laboratory Medicine,2015,30(05):129.[doi:10.3969/j.issn.1671-7414.2015.03.039]
[2]邱 爽,孟瑞芳,蒋筱漪,等.血清免疫固定电泳、蛋白电泳、免疫球蛋白及轻链定量在诊断多发性骨髓瘤中的临床应用[J].现代检验医学杂志,2015,30(02):61.[doi:10.3969/j.issn.1671-7414.2015.02.019]
QIU Shuang,MENG Rui-fang,JIANG Xiao-yi,et al.Clinical Application of Immunofixtion Electrophoresis,
Serum Protein Electrophoresis and Immunoglobulins and Light Chain
Quantitative Analysis in the Diagnosis of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2015,30(05):61.[doi:10.3969/j.issn.1671-7414.2015.02.019]
[3]李 瑛,李 军.多发性骨髓瘤患者血清中IL-6与IL-27水平监测的临床应用[J].现代检验医学杂志,2016,31(04):87.[doi:10.3969/j.issn.16717-414.2016.04.023]
LI Ying,LI Jun.Clinical Application of Monitoring IL-6 and IL-27 Levels
in Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2016,31(05):87.[doi:10.3969/j.issn.16717-414.2016.04.023]
[4]郭进京,胡林辉,陶千山,等.红细胞分布宽度在多发性骨髓瘤患者预后分期中的价值[J].现代检验医学杂志,2017,32(03):34.[doi:10.3969/j.issn.1671-7414.2017.03.009]
GUO Jin-jing,HU Lin-hui,TAO Qian-shan,et al.Value of Red Cell Distribution Width
in the Prognosis of Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2017,32(05):34.[doi:10.3969/j.issn.1671-7414.2017.03.009]
[5]谭 奎,沈婵娟,张 玲,等.多发性骨髓瘤患者骨髓CD269和CD317基因的差异性表达研究[J].现代检验医学杂志,2017,32(06):64.[doi:10.3969/j.issn.1671-7414.2017.06.001]
TAN Kui,SHEN Chan-juan,ZHANG Ling,et al.Differential Expression of CD269 and CD317 Genes
in Bone Marrow of Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2017,32(05):64.[doi:10.3969/j.issn.1671-7414.2017.06.001]
[6]盘国雄,谭才燕,何嘉颖,等.多发性骨髓瘤患者血清中lncRNA PCAT-1的表达水平与临床预后研究[J].现代检验医学杂志,2018,33(01):72.[doi:10.3969/j.issn.1671-7414.2018.01.001]
PAN Guo-xiong,TAN Cai-yan,HE Jia-ying,et al.Serum LncRNA PCAT-1 Expression Level of Patients
with Multiple Myeloma and Clinical Value[J].Journal of Modern Laboratory Medicine,2018,33(05):72.[doi:10.3969/j.issn.1671-7414.2018.01.001]
[7]刘玉霞,胡国瑜,袁朝晖,等.CD269和CD317在多发性骨髓瘤中的表达及临床意义[J].现代检验医学杂志,2018,33(02):58.[doi:10.3969/j.issn.1671-7414.2018.02.001]
LIU Yu-xia,HU Guo-yu,YUAN Chao-hui,et al.Expression of CD269 and CD317 in Multiple Myeloma
and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2018,33(05):58.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[8]夏 芳a,汪隆海a,方 超a,等.血清5种生物标志物水平联合检测对心力衰竭的诊断价值[J].现代检验医学杂志,2019,34(04):22.[doi:10.3969/j.issn.1671-7414.2019.04.006]
XIA Fanga,WANG Long-haia,FANG Chaoa,et al.Combined Detection of Serum 5 Biomarkers
for the Diagnostic Value of Heart Failure[J].Journal of Modern Laboratory Medicine,2019,34(05):22.[doi:10.3969/j.issn.1671-7414.2019.04.006]
[9]李泽东,詹 贞,刘 忆,等.帕金森病患者血清鳞状细胞癌抗原（SCC-Ag）表达的临床意义[J].现代检验医学杂志,2019,34(06):70.[doi:10.3969 ／ j.issn.1671-7414.2019.06.017]
LI Ze-dong,ZHAN Zhen,LIU Yi,et al.Significance of SCC Antigen Expression in Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2019,34(05):70.[doi:10.3969 ／ j.issn.1671-7414.2019.06.017]
[10]张 蓉,李国辉,刘小五,等.初诊多发性骨髓瘤患者外周血淋巴细胞绝对值/ 单核细胞绝对值比值在预测临床预后的价值研究[J].现代检验医学杂志,2020,35(01):101.[doi:10.3969/j.issn.1671-7414.2020.01.027]
ZHANG Rong,LI Guo-hui,LIU Xiao-wu,et al.Value of Peripheral Blood Lymphocyte Absolute Value/Monocyte Absolute
Value Ratio in Predicting Clinical Prognosis of Newly Diagnosed MultipleMyeloma Patients[J].Journal of Modern Laboratory Medicine,2020,35(05):101.[doi:10.3969/j.issn.1671-7414.2020.01.027]